TickerGuard
Buy Day today: Neutral (48) Mixed market breadth · no major macro event
NERV

Minerva Neurosciences Inc

Healthcare · Biotechnology

3.40$ +0.0% vs. previous close Closing price · As of: Sep 28, 2026

Ownership

Ownership Structure

Who owns Minerva Neurosciences Inc (NERV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.8% of the shares are freely tradable; institutional investors hold 100.2%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 100.2%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 3.3%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 71.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 4.6%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 48Mio.

Largest Shareholders

Institutions

Institutions NERV
Name Stake (%) Shares Change (%) Date
Federated Hermes Inc 9.78 4,670,426 -8.7 06/30/2026
Vivo Capital, LLC 9.05 4,322,747 +0.0 06/30/2026
HHG PLC 8.99 4,294,259 +47,614.0 03/31/2026
Balyasny Asset Management LLC 8.92 4,258,600 +0.0 03/31/2026
Logos Global Management LP 6.89 3,288,777 +2.3 06/30/2026
Farallon Capital Management, L.L.C. 4.95 2,365,000 +0.0 03/31/2026
Ally Bridge Group (NY) LLC 4.56 2,175,802 +31.4 06/30/2026
Foresite Capital Management VI LLC 4.16 1,985,584 -0.1 06/30/2026
Vanguard Capital Management, LLC 3.87 1,845,831 +0.0 03/31/2026
Spruce Street Capital LP 3.47 1,655,500 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?